Drugs & Targets FDA approves Retevmo for medullary thyroid cancer with RET mutation October 04, 2024Vol.50 No.37
Drugs & Targets FDA approves Cologuard Plus Test for non-invasive CRC screening October 04, 2024Vol.50 No.37
Drugs & Targets FDA approves Sarclisa + VRd for MM not eligible for transplant September 27, 2024Vol.50 No.36
Drugs & Targets Bayer submits sNDA to FDA for expanded indication for Nubeqa for treatment of mHSPC September 27, 2024Vol.50 No.36
Regulatory News Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover designThe agency accepts the invitation September 20, 2024Vol.50 No.35By Paul Goldberg
Drugs & Targets FDA approves Keytruda + pemetrexed + chemo in first-line mesothelioma indication September 20, 2024Vol.50 No.35
Drugs & Targets FDA approves Rybrevant + pemetrexed + chemo in NSCLC with EGFR exon 19 deletions or L858R mutations September 20, 2024Vol.50 No.35
Drugs & Targets FDA approves Kisqali + aromatase inhibitor for early high-risk breast cancer September 20, 2024Vol.50 No.35
Drugs & Targets FDA grants Fast Track designation for ICT01 + Azacitidine + Venetoclax in treatment of first-line AML unfit for induction chemo September 20, 2024Vol.50 No.35
